CVS Health Co. (NYSE:CVS) Shares Sold by Raab & Moskowitz Asset Management LLC

Raab & Moskowitz Asset Management LLC decreased its holdings in CVS Health Co. (NYSE:CVS) by 3.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,959 shares of the pharmacy operator’s stock after selling 622 shares during the quarter. Raab & Moskowitz Asset Management LLC’s holdings in CVS Health were worth $1,260,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Bryn Mawr Capital Management LLC increased its holdings in CVS Health by 74.0% in the third quarter. Bryn Mawr Capital Management LLC now owns 43,213 shares of the pharmacy operator’s stock valued at $3,017,000 after buying an additional 18,385 shares during the last quarter. Value Partners Investments Inc. grew its holdings in shares of CVS Health by 26.5% during the third quarter. Value Partners Investments Inc. now owns 991,601 shares of the pharmacy operator’s stock valued at $69,261,000 after purchasing an additional 207,702 shares during the last quarter. Sonora Investment Management Group LLC grew its holdings in shares of CVS Health by 1.6% during the third quarter. Sonora Investment Management Group LLC now owns 50,488 shares of the pharmacy operator’s stock valued at $3,525,000 after purchasing an additional 774 shares during the last quarter. Checchi Capital Advisers LLC grew its holdings in shares of CVS Health by 2.3% during the third quarter. Checchi Capital Advisers LLC now owns 10,405 shares of the pharmacy operator’s stock valued at $726,000 after purchasing an additional 233 shares during the last quarter. Finally, Personal CFO Solutions LLC grew its holdings in shares of CVS Health by 2.6% during the third quarter. Personal CFO Solutions LLC now owns 19,355 shares of the pharmacy operator’s stock valued at $1,351,000 after purchasing an additional 491 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Performance

CVS opened at $67.18 on Friday. The company has a market capitalization of $84.68 billion, a price-to-earnings ratio of 10.40, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. CVS Health Co. has a 1-year low of $64.41 and a 1-year high of $83.25. The business has a 50 day moving average price of $74.42 and a two-hundred day moving average price of $73.66.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The firm had revenue of $93.81 billion during the quarter, compared to the consensus estimate of $90.58 billion. During the same period in the prior year, the firm posted $1.99 earnings per share. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Research analysts predict that CVS Health Co. will post 8.31 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date of this dividend is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.96%. CVS Health’s dividend payout ratio (DPR) is presently 41.18%.

Insider Activity

In other news, EVP Prem S. Shah sold 29,473 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now owns 39,765 shares in the company, valued at approximately $3,059,916.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.24% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of CVS Health in a report on Monday, February 26th. Royal Bank of Canada lowered their target price on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a report on Thursday, February 8th. Wells Fargo & Company lowered their target price on CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $87.00 price objective on shares of CVS Health in a research report on Wednesday, April 10th. Finally, SVB Leerink initiated coverage on CVS Health in a research report on Monday, February 26th. They set an “outperform” rating and a $88.00 price objective for the company. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $89.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.